Credit: Shutterstock. The approval was based on data from the phase 3 AGILE trial. The Food and Drug Administration (FDA) has approved Tibsovo ® (ivosidenib) in combination with azacitidine for newly ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...
Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...
CEO Jim Dentzer introduced Dr. Ahmed Hamdy as the new Chief Medical Officer, citing his experience with ibrutinib and acalabrutinib as highly relevant to advancing emavusertib. The TakeAim lymphoma ...
Management reaffirmed the timeline to enroll the additional 30-40 patients in the TakeAim lymphoma study within 12-18 months to support accelerated regulatory filings. The expected responses required ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback